Allen Robert D. III sold $29K of IVVD
Allen Robert D. III (Chief Scientific Officer) sold 37,722 shares of Invivyd, Inc. (IVVD) at an average of $0.78 ($0.72–$0.84) across 2 trades over 2026-08-17 to 2026-08-18 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the insider’s open-market sale size, price range, and that it was executed under a pre-arranged 10b5-1 plan. This typically has limited fundamental impact but can influence near-term sentiment.
Market read
Traders may monitor IVVD for any follow-on insider activity, but the disclosure alone does not provide new operational or regulatory catalysts.
What to watch
The filing does not disclose whether other insiders or the company made offsetting purchases, nor does it provide context on total insider holdings beyond the post-transaction share count.
Background
The article is an SEC Form 4 insider transaction disclosure for Invivyd, Inc. (IVVD).
Ticker impact
Invivyd disclosed via Form 4 that Chief Scientific Officer Allen Robert D. III sold 37,722 shares in open-market trades under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.
The filing is a routine Form 4 open-market sale with a pre-arranged 10b5-1 plan, and it provides no new guidance, trial, or regulatory information.
Market effects
Minimal. Insider selling at a single biotech does not, by itself, reset sector risk or valuation assumptions.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect liquidity planning rather than negative expectations, so any bearish read-through could be overstated.
Key entities
- issuerInvivyd, Inc.
Company subject of the Form 4 insider transaction disclosure.
- insiderAllen Robert D. III
Chief Scientific Officer who sold shares in open-market trades under a 10b5-1 plan.
